Drug · CHEMBL1908391
MASITINIB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MASITINIB. Drugs and targets, record CHEMBL1908391. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1908391
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| FGFR3 | Fibroblast growth factor receptor 3 | Fibroblast growth factor receptor 3 inhibitor | INHIBITOR | https://conductscience.org/library/genes/2261 |
| KIT | Mast/stem cell growth factor receptor Kit | Stem cell growth factor receptor inhibitor | INHIBITOR | https://conductscience.org/library/genes/3815 |
| PDGFRA | Platelet-derived growth factor receptor | Platelet-derived growth factor receptor inhibitor | INHIBITOR | https://conductscience.org/library/genes/5156 |
| PDGFRB | Platelet-derived growth factor receptor | Platelet-derived growth factor receptor inhibitor | INHIBITOR | https://conductscience.org/library/genes/5159 |
Source ChEMBL
Diseases22
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| gastrointestinal stromal tumor | Phase 3 | ClinicalTrials.gov and TTD | 7 | 5 | https://conductscience.org/library/drugs?q=MONDO_0011719 |
| amyotrophic lateral sclerosis | Phase 3 | ClinicalTrials.gov and TTD | 6 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004976 |
| multiple sclerosis symptom measurement | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | https://conductscience.org/library/drugs?q=EFO_0803536 |
| Alzheimer disease | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004975 |
| asthma | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004979 |
| rheumatoid arthritis | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0008383 |
| systemic mastocytosis | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0016586 |
| mastocytosis | Phase 2 | ClinicalTrials.gov | 3 | 2 | https://conductscience.org/library/drugs?q=MONDO_0007950 |
| COVID-19 | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| colorectal cancer | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
1 to 10 of 22Source Open Targets
See all 22 diseasesTrials38
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05441488 | Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis | Phase 3 | 800 | masitinib | Its name | ClinicalTrials.gov | |
| NCT01872598 | Masitinib in Patients With Mild to Moderate Alzheimer's Disease | Phase 3 | 721 | masitinib | Its name | ClinicalTrials.gov | |
| NCT03761225 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | Phase 3 | 714 | masitinib | Its name | ClinicalTrials.gov | |
| NCT01433497 | Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis | Phase 3 | 656 | masitinib | Its name | ClinicalTrials.gov | |
| NCT05564169 | Masitinib in Patients With Mild Alzheimer's Disease | Phase 3 | 600 | masitinib | Its name | ClinicalTrials.gov | |
| NCT03127267 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Phase 3 | 495 | masitinib | Its name | ClinicalTrials.gov | |
| NCT01449162 | Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids | Phase 3 | 420 | masitinib | Its name | ClinicalTrials.gov | |
| NCT07174492 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | Phase 3 | 412 | masitinib | Its name | ClinicalTrials.gov | |
| NCT02588677 | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) | Phase 2/3 | 394 | masitinib | Its name | ClinicalTrials.gov | |
| NCT03766295 | Masitinib Plus Gemcitabine in Pancreatic Cancer | Phase 3 | 377 | masitinib | Its name | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials13
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Paced Visual Serial Addition Test | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908391
GET https://conductscience.org/api/drugs/v1/CHEMBL1908391/diseases?page=2